Financial forecasts and twelve-month price targets for Lyell Immunopharma (LYEL) compiled by equity research analysts span a broad range, reflecting the highly speculative nature of clinical-stage biotechnology equities. Wall Street projections depend heavily on anticipated clinical trial readouts for its lead oncology programs, cash burn management, and regulatory updates. Because biotech valuations shift dramatically based on trial success or failure, market analysts treat price predictions as probabilistic models rather than certainties, prompting investors to weigh pipeline risks carefully.